Chronic myelogenous leukaemia market.
Storey
Shane
S
D001549:Benzamides; D000069439:Dasatinib; D004345:Drug Industry / Q000191:economics / Q000639:trends; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000191:economics*; D040541:Marketing / Q000191:economics / Q000639:trends*; D010879:Piperazines / Q000191:economics / Q000627:therapeutic use; D011743:Pyrimidines / Q000191:economics / Q000627:therapeutic use; D013844:Thiazoles / Q000191:economics / Q000627:therapeutic use
D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D013844:Thiazoles; D000068877:Imatinib Mesylate; C498826:nilotinib; D000069439:Dasatinib